Skip to main content
. 2022 Mar 23;9(2):ENEURO.0434-21.2022. doi: 10.1523/ENEURO.0434-21.2022

Figure 1.

Figure 1.

The viability of HEI-OC1 cells with the treatment of designed concentration of cisplatin (a), agmatine (b), and different concentration of agmatine and 30 μm cisplatin (c) for 24 h. Data were represented as mean ± SD, n = 3; *p <0.05, **p <0.01 compared with control group; #p <0.05, ##p <0.01 compared with 30 μm cisplatin only group.